论文部分内容阅读
目的:观察孟鲁司特辅助治疗儿童支气管哮喘的疗效和不良反应及其对患儿复发的影响。方法:180例儿童支气管哮喘患儿随机分为对照组与观察组各90例。对照组采用吸氧、布地奈德联合特布他林雾化吸入、甲泼尼龙琥珀酸钠静滴等常规治疗;观察组在对照组基础上加用孟鲁司特钠片5 mg,po,qd。两组均连续治疗3个月后评价疗效,观察两组呼吸困难及喘息、哮鸣音消失时间,以及治疗期间的药品不良反应。随访3~6个月,比较两组复发情况。结果:观察组呼吸困难、喘息及哮鸣音消失时间均明显短于对照组(P<0.05);总有效率为96.67%,明显高于对照组的73.33%(P<0.05)。两组平均随访(5.1±0.3)个月,观察组治愈后复发率为8.51%,明显低于对照组的31.43%(P<0.05)。两组治疗期间未见明显药品不良反应发生。结论:常规药物治疗基础上加用孟鲁司特迅速改善临床症状,提高治疗效果,减少治愈后复发情况,安全性高,值得临床推广应用。
Objective: To observe the efficacy and adverse reactions of Montelukast adjuvant therapy in children with bronchial asthma and its effect on recurrence in children. Methods: 180 cases of children with bronchial asthma were randomly divided into control group and observation group of 90 cases. The control group was treated with inhalation of oxygen, budesonide combined with terbutaline, inhaled methylprednisolone sodium succinate and other conventional treatment; the observation group in the control group based on the use of montelukast sodium 5 mg, po, qd. Two groups were treated for 3 months after treatment to evaluate the efficacy of two groups were observed dyspnea and wheezing, wheeze disappear time, and adverse drug reactions during treatment. Followed up for 3 to 6 months, compared the recurrence of the two groups. Results: The duration of breathlessness, wheezing and wheeze disappeared in the observation group was significantly shorter than that in the control group (P <0.05). The total effective rate was 96.67%, significantly higher than that of the control group (73.33%, P <0.05). The average follow-up time was (5.1 ± 0.3) months in both groups. The recurrence rate of the observation group after treatment was 8.51%, which was significantly lower than that of the control group (31.43%, P <0.05). No significant adverse drug reactions occurred during the two treatment periods. Conclusion: Based on routine drug therapy, montelukast can improve clinical symptoms, improve the curative effect and reduce the recurrence after cure, which is safe and worthy of clinical application.